Insight Molecular Diagnostics Inc.
NASDAQ:IMDXMedical - Diagnostics & Research
Healthcare
$1.59 +2.44%
+$0.13 today
- Market cap
- $52.08M
- Beta
- 1.79
- P/E (TTM)
- -3.9
- EPS (TTM)
- -$1.39
52W Low $2.33High $8.51
Volume 0.64M
Average 0.38M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$22.18M
FY 2025 · Annual
Investing Cash Flow
-$3.19M
FY 2025 · Annual
Financing Cash Flow
$28.07M
FY 2025 · Annual
+37.4% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (64.1M) | (72.9M) | (27.78M) | (60.66M) | (50.22M) |
| Depreciation & Amortization | 4.21M | 5.22M | 1.68M | 1.56M | 2.2M |
| Deferred Income Tax | (9.26M) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 6.84M | 10.04M | 6.57M | 1.91M | 2.22M |
| Change in Working Capital | 149K | (1.94M) | (3.97M) | (1.32M) | 2.73M |
| Accounts Receivables | (1.23M) | (575K) | 109K | (1.13M) | 485K |
| Inventory | 0 | 0 | 0 | (410K) | (36K) |
| Accounts Payables | (1.35M) | 297K | (4.76M) | 967K | 2.65M |
| Other Working Capital | 2.73M | (1.66M) | 677K | (749K) | (368K) |
| Other Non-Cash Items | 26.22M | 14.01M | 174K | 37.79M | 20.9M |
| Operating Cash Flow | (35.94M) | (45.57M) | (23.33M) | (20.71M) | (22.18M) |
| Capital Expenditures | (2.25M) | (4.34M) | (281K) | (516K) | (3.19M) |
| Acquisitions (Net) | (11.71M) | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 367K | 0 | 0 |
| Other Investing Activities | 0 | 0 | (1.02M) | 4K | 0 |
| Investing Cash Flow | (13.96M) | (4.34M) | (932K) | (512K) | (3.19M) |
| Debt Repayment | (1.53M) | (1.43M) | (117K) | (201K) | (510K) |
| Common Stock Issued | 77.99M | 32.84M | 13.85M | 27.81M | 28.66M |
| Common Stock Repurchased | (239K) | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 2.15M | (483K) | (427K) | (1.8M) | (74K) |
| Financing Cash Flow | 78.36M | 35.81M | 12.19M | 20.43M | 28.07M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 973K |
| Net Change in Cash | 28.46M | (14.1M) | (12.07M) | (796K) | 3.68M |
| Free Cash Flow | (38.19M) | (49.91M) | (23.61M) | (21.23M) | (25.37M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$50.2M
+ D&A$2.2M
+ Stock-Based Comp$2.2M
+ Deferred Tax$0
+ Working Capital$2.7M
+ Other Non-Cash$20.9M
= Operating Cash Flow-$22.2M
- Capex-$3.2M
= Free Cash Flow-$25.4M
Analysis
FY2025 free cash flow is -$25.4M. FCF conversion is 50.5% of net income. Operating cash flow was -$22.2M, with capex of -$3.2M. The largest bridge item is Other Non-Cash at $20.9M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Sep 21, 2026 | |
| 10-Q | Quarterly report | Aug 10, 2026 | |
| 8-K | Current report | Aug 10, 2026 | |
| S-8 | S-8 filing | Jul 24, 2026 | |
| 4 | Statement of changes in beneficial ownership | Jul 6, 2026 |
Does IMDX generate free cash flow?
Insight Molecular Diagnostics Inc. (IMDX) generated -$25.37M of free cash flow in fiscal 2025.
How much operating cash flow does IMDX produce?
Operating cash flow was -$22.18M, before capital expenditures of $3.19M.
Continue the stock analysis
Jump to another research area for this company.